Still hope for schistosomiasis vaccine

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 10, 2015, Pages 2504-2508

  Ricciardi, Alessandra ^a,b   Ndao, Momar ^a,b  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Clinical trial; Neglected tropical disease; Public health; Schistosomiasis; Vaccine

Indexed keywords

BACTERIAL VECTOR; CATHEPSIN B; DINUCLEOTIDE; DNA VACCINE; GLUCOPYRANOSYL LIPID; GLUTATHIONE TRANSFERASE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IPOPROTEIN RECEPTOR; PRAZIQUANTEL; PROTEIN P80; TETRASPANIN; UNCLASSIFIED DRUG; PARASITE ANTIGEN; VACCINE;

DISEASE TRANSMISSION; ESCHERICHIA COLI; FASCIOLIASIS; HELPER CELL; HUMAN; IMMUNIZATION; INFECTION RISK; KOMAGATAELLA PASTORIS; NONHUMAN; NOTE; PROTEIN EXPRESSION; PUBLIC HEALTH; SCHISTOSOMA HAEMATOBIUM; SCHISTOSOMIASIS; ANIMAL; DRUG DEVELOPMENT; IMMUNOLOGY; ISOLATION AND PURIFICATION; PROCEDURES; SCHISTOSOMA; TRENDS;

ANIMALS; ANTIGENS, HELMINTH; DRUG DISCOVERY; HUMANS; SCHISTOSOMA; SCHISTOSOMIASIS; VACCINES;

EID: 84943149105     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1059981     Document Type: Note

References (45)

1. Chitsulo L, Engels D, Montresor A, Savioli L. The global status of schistosomiasis and its control. Acta Trop 2000;77:41-51; PMID:10996119; http://dx.doi.org/10.1016/S0001-706X(00)00122-4
2. Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomiasis. Lancet 2006;368:1106-1118, PMID:16997665; http://dx.doi.org/10.1016/S0140-6736(06)69440-3
3. King CH, Dangerfield-Cha M. The unacknowledged impact of chronic schistosomiasis. Chronic Illn 2008;4:65-79, PMID:18322031; http://dx.doi.org/10.1177/1742395307084407
4. Terer CC, Bustinduy AL, Magtanong RV, Muhoho N, Mungai PL, Muchiri EM, Kitron U, King CH, Mutuku FM. Evaluation of the health-related quality of life of children in Schistosoma haematobium-endemic communities in Kenya:a cross-sectional study. PLoS Negl Trop Dis 2013;7:e2106, PMID:23505590; http://dx.doi.org/10.1371/journal.pntd.0002106
5. Wu W, Wang W, Huang YX. New insight into praziquantel against various developmental stages of schistosomes. Parasitol Res 2011;109:1501-1507, PMID:21984370; http://dx.doi.org/10.1007/s00436-011-2670-3
6. Doenhoff MJ, Kusel JR, Coles GC, Cioli D. Resistance of Schistosoma mansoni to praziquantel:is there a problem? Trans R Soc Trop Med Hyg 2002;96:465-469, PMID:12474468; http://dx.doi.org/10.1016/S0035-9203(02)90405-0
7. Hotez PJ, Fenwick A. Schistosomiasis in Africa:an emerging tragedy in our global health decade. PLoS Negl Trop Dis 2009;3:e485, PMID:19787054; http://dx.doi.org/10.1371/journal.pntd.0000485
8. Tendler M, Simpson AJ. The biotechnology-value chain:development of Sm14 as a schistosomiasis vaccine. Acta Trop 2008;108:263-266, PMID:18834847; http://dx.doi.org/10.1016/j.actatropica.2008.09.002
9. WHO. PCT databank 2013 [updated 2013 cited 8 March2013] http://www.who.int/neglected_diseases/preventive_chemotherapy/sch/en/index.html
10. Bergquist NR, Leonardo LR, Mitchell GF. Vaccinelinked chemotherapy:can schistosomiasis control benefit from an integrated approach? Trends Parasitol 2005;21:112-117, PMID:15734657; http://dx.doi.org/10.1016/j.pt.2005.01.001
11. Bergquist R, Utzinger J, McManus DP. Trick or treat: the role of vaccines in integrated schistosomiasis control. PLoS Negl Trop Dis 2008;2:e244, PMID:18575619; http://dx.doi.org/10.1371/journal.pntd.0000244
12. Berriman M, Haas BJ, LoVerde PT, Wilson RA, Dillon GP, Cerqueira GC, Mashiyama ST, Al-Lazikani B, Andrade LF, Ashton PD, et al. The genome of the blood fluke Schistosoma mansoni. Nature 2009;460:352-358, PMID:19606141; http://dx.doi.org/10.1038/nature08160
13. Schistosoma japonicum Genome Sequencing and Functional Analysis Consortium. The Schistosoma japonicum genome reveals features of host-parasite interplay. Nature 2009;460:345-351, PMID:19606140; http://dx.doi.org/10.1038/nature08140
14. Young ND, Jex AR, Li B, Liu S, Yang L, Xiong Z, Li Y, Cantacessi C, Hall RS, Xu X, et al. Whole-genome sequence of Schistosoma haematobium. Nat Genet 2012 44:221-225, PMID:22246508; http://dx.doi.org/10.1038/ng.1065
15. Ganley-Leal LM, Guarner J, Todd CW, Da’Dara AA, Freeman GL Jr, Boyer AE, Harn DA, Secor WE. Comparison of Schistosoma mansoni irradiated cercariae and Sm23 DNA vaccines. Parasite Immunol 2005;27:341-349, PMID:16149992; http://dx.doi.org/10.1111/j.1365-3024.2005.00785.x
16. Minard P, Dean DA, Jacobson RH, Vannier WE, Murrell KD. Immunization of mice with cobalt-60 irradiated Schistosoma mansoni cercariae. Am J Trop Med Hyg 1978;27:76-86, PMID:626284
17. Sher A, Hieny S, James SL, Asofsky R. Mechanisms of protective immunity against Schistosoma mansoni infection in mice vaccinated with irradiated cercariae. II. Analysis of immunity in hosts deficient in T lymphocytes, B lymphocytes, or complement. J Immunol 1982;128:1880-1884, PMID:6801124
18. Kariuki TM, Farah IO, Yole DS, Mwenda JM, Van Dam GJ, Deelder AM, Wilson RA, Coulson PS. Parameters of the attenuated schistosome vaccine evaluated in the olive baboon. Infect Immun 2004 72:5526-5529, PMID:15322059; http://dx.doi.org/10.1128/IAI.72.9.5526-5529.2004
19. Bethony JM, Cole RN, Guo X, Kamhawi S, Light-owlers MW, Loukas A, Petri w, Reed S, Valenzuela JG, Hotez PJ. Vaccines to combat the neglected tropical diseases. Immunol Rev 2011 239:237-270, PMID:21198676; http://dx.doi.org/10.1111/j.1600-065X.2010.00976.x
20. Capron A, Capron M, Dombrowicz D, Riveau G. Vac-cine strategies against schistosomiasis:from concepts to clinical trials. Int Arch Allergy Immunol 2001 124:9-15; PMID:11306914; http://dx.doi.org/10.1159/000053656
21. Tendler M, Brito CA, Vilar MM, Serra-Freire N, Diogo CM, Almeida MS, Delbem AC, Da Silva JF, Savino W, Garratt RC, et al. A Schistosoma mansoni fatty acid-binding protein, Sm14, is the potential basis of a dual-purpose anti-helminth vaccine. Proc Natl Acad Sci USA 1996 93:269-273
22. https://clinicaltrials.gov/ct2/show/NCT01154049. Accessed on May 2015
23. Tran MH, Pearson MS, Bethony JM, Smyth DJ, Jones MK, Duke M, Don TA, McManus DP, Correa-Oli-veira R, Loukas A. Tetraspanins on the surface of Schistosoma mansoni are protective antigens against schistosomiasis. Nat Med 2006 12:835-840, PMID:16783371; http://dx.doi.org/10.1038/nm1430
24. Da’dara AA, Li YS, Xiong T, Zhou J, Williams GM, McManus DP, Feng Z, Yu XL, Gray DJ, Harn DA. DNA-based vaccines protect against zoonotic schistosomiasis in water buffalo. Vaccine 2008 26:3617-3625, PMID:18524429; http://dx.doi.org/10.1016/j.vaccine.2008.04.080
25. Curti E, Kwityn C, Zhan B, Gillespie P, Brelsford J, Deumic V, Pileskatt J, Rezende WC, Tsao E, Kalampa-nayil B, et al. Expression at a 20L scale and purification of the extracellular domain of the Schistosoma mansoni TSP-2 recombinant protein:a vaccine candidate for human intestinal schistosomiasis. Hum Vaccin Immunother 2013 9:2342-2350, PMID:23899507; http://dx.doi.org/10.4161/hv.25787
26. Ahmad G, Zhang W, Torben W, Haskins C, Diggs S, Noor Z, Le L, Siddiqui AA. Prime-boost and recombinant protein vaccination strategies using Sm-p80 protects against Schistosoma mansoni infection in the mouse model to levels previously attainable only by the irradiated cercarial vaccine. Parasitol Res 2009 105:1767-1777, PMID:19809833; http://dx.doi.org/10.1007/s00436-009-1646-z
27. Ahmad G, Zhang W, Torben W, Ahrorov A, Damian RT, Wolf RF, White GL, Carey DW, Mwinzi PN, Ganley-Leal L, et al. Preclinical prophylactic efficacy testing of Sm-p80-based vaccine in a nonhuman primate model of Schistosoma mansoni infection and immunoglobulin G and E responses to Sm-p80 in human serum samples from an area where schistosomiasis is endemic. J Infect Dis 2011 204:1437-1449, PMID:21921206; http://dx.doi.org/10.1093/infdis/jir545
28. Karmakar S, Zhang W, Ahmad G, Torben W, Alam MU, Le L, Damian RT, Wolf RF, White GL, Carey DW, et al. Cross-species protection:Schistosoma mansoni sm-p80 vaccine confers protection against Schistosoma haematobium in hamsters and baboons. Vaccine 201432:1296-1303, PMID:24397898; http://dx.doi. org/10.1016/j.vaccine.2013.12.057
29. Ricciardi A, Dalton JP, Ndao M. Evaluation of the immune response and protective efficacy of Schistosoma mansoni Cathepsin B in mice using CpG dinucleotides as adjuvant. Vaccine 2015 33:346-353; PMID:25448114; http://dx.doi.org/10.1016/j.vaccine.2014.11.016
30. McManus DP, Loukas A. Current status of vaccines for schistosomiasis. Clin Microbiol Rev 2008 21:225-242, PMID:18202444; http://dx.doi.org/10.1128/CMR.00046-07
31. http://dailydose.ttuhsc.edu/news/school-of-medicine/ttuhsc-receives-national-grant-2/. Accessed on May 2015
32. King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helminth infection:a meta-analysis of disability-related outcomes in endemic schistosomiasis. Lancet 2005 365:1561-1569, PMID:15866310; http://dx.doi.org/10.1016/S0140-6736(05)66457-4
33. Ribeiro de Jesus A, Araujo I, Bacellar O, Magalhaes A, Pearce E, Harn D, Strand M, Carvalho EM. Human immune responses to Schistosoma mansoni vaccine candidate antigens. Infect Immun 2000 68:2797-2803, PMID:10768975; http://dx.doi.org/10.1128/IAI.68.5.2797-2803.2000
34. Acosta LP, Aligui GD, Tiu WU, McManus DP, Olveda RM. Immune correlate study on human Schis-tosoma japonicum in a well-defined population in Leyte, Philippines:I. Assessment of “resistance” versus “susceptibility to S. japonicum infection. Acta Trop 2002 84:127-136, PMID:12429429; http://dx.doi.org/10.1016/S0001-706X(02)00176-6
35. Acosta LP, Waine G, Aligui GD, Tiu WU, Olveda RM, McManus DP. Immune correlate study on human Schistosoma japonicum in a well-defined population in Leyte, Philippines:II. Cellular immune responses to S. japonicum recombinant and native antigens. Acta Trop 2002 84:137-149, PMID:12429430; http://dx.doi.org/10.1016/S0001-706X(02)00177-8
36. Al-Sherbiny M, Osman A, Barakat R, El Morshedy H, Bergquist R, Olds R. In vitro cellular and humoral responses to Schistosoma mansoni vaccine candidate antigens. Acta Trop 2003 88:117-130; PMID:14516923; http://dx.doi.org/10.1016/S0001-706X(03)00195-5
37. Spiegel H, Boes A, Kastilan R, Kapelski S, Edgue G, Beiss V, Chubodova I, Scheuermayer M, Pradel G, Schillberg S, et al. The stage-specific in vitro efficacy of a malaria cocktail provides valuable insights into the development of effective multi-stage vaccines. Biotechnol J 2015., PMID:25913888; http://dx.doi.org/10.1002/biot.201500055
38. Jain K, Jain NK. Vaccines for visceral leishmaniasis:A review. J Immunol Methods 2015; 422:12, PMID: 25858230; http://dx.doi.org/10.1016/j.jim.2015.03.017
39. Geiger SM. Immuno-epidemiology of Schistosoma mansoni infections in endemic populations co-infected with soil-transmitted helminths:present knowledge, challenges, and the need for further studies. Acta Trop 2008 108:118-123, PMID:18582842; http://dx.doi.org/10.1016/j.actatropica.2008.05.012
40. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010:a systematic analysis for the Global Brden of Disease Study 2010. Lancet 2012 380:2163-2196, PMID:23245607; http://dx.doi.org/10.1016/S0140-6736(12)61729-2
41. Hotez PJ, Kamath A. Neglected tropical diseases in sub-saharan Africa:review of their prevalence, distribution, and disease burden. PLoS Negl Trop Dis 2009 3:e412, PMID:19707588; http://dx.doi.org/10.1371/journal.pntd.0000412
42. Hotez PJ, Bethony JM, Diemert DJ, Pearson M, Lou-kas A. Developing vaccines to combat hookworm infection and intestinal schistosomiasis. Nat Rev Microbiol 2010 8:814-826, PMID:20948553; http://dx.doi.org/10.1038/nrmicro2438
43. Goud GN, Bottazzi ME, Zhan B, Mendez S, Deumic V, Pileskatt J, Liu S, Wang Y, Bueno L, Fujiwara R, et al. Expression of the Necator americanus hookworm larval antigen Na-ASP-2 in Pichia pastoris and purification of the recombinant proein for use in human clinical trials. Vaccine 2005 23:4754-4764, PMID:16054275; http://dx.doi.org/10.1016/j.vaccine.2005.04.040
44. Damian RT, de la Rosa MA, Murfin DJ, Rawlings CA, Weina PJ, Xue YP. Further development of the baboon as a model for acute schistosomiasis. Mem Inst Oswaldo Cruz 1992 87:261-269, PMID:1343906; http://dx.doi.org/10.1590/S0074-02761992000800041
45. Kennedy RC, Shearer MH, Hildebrand W. Nonhuman primate model to evaluate vaccine safety and immuno-genicity. Vaccine 1997 15:903-908, PMID:9234544; http://dx.doi.org/10.1016/S0264-410X(96)00277-0